Tricida to Present at the Needham Virtual Healthcare Conference
Rhea-AI Summary
Tricida, Inc. (Nasdaq: TCDA) will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 10:30 AM PT. The presentation will include a company overview and updates on key initiatives. A live webcast will be available on the Tricida website, with an archive accessible for 90 days post-presentation.
Tricida specializes in developing veverimer, an investigational drug aimed at slowing chronic kidney disease (CKD) progression in patients with metabolic acidosis. Currently, there are no FDA-approved therapies for this condition affecting approximately 4.3 million CKD patients in the U.S.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TCDA gained 11.56%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today that it will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 10:30 am Pacific Time / 1:30 pm Eastern Time. Tricida will provide a company overview, business update and progress on its key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis and CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately 4.3 million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD.
For more information about Tricida, please visit www.tricida.com.
Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com
FAQ
What is the date and time of Tricida's presentation at the Needham Virtual Healthcare Conference?
Where can I watch Tricida's presentation from the Needham Conference?
What is the focus of Tricida's investigational drug candidate veverimer?
How many patients with chronic kidney disease are affected by metabolic acidosis in the U.S.?
Is there an FDA-approved therapy for metabolic acidosis in chronic kidney disease patients?
